Development and validation of a rapid and high-sensitivity liquid chromatography-tandem mass spectrometry assay for the determination of neostigmine in small-volume beagle dog plasma and its application to a pharmacokinetic study

Investigation of CYP2B6, 3A4 and β-esterase interactions of Withania somnifera (L.) dunal in human liver microsomes and HepG2 cells

ETHNOPHARMACOLOGICAL RELEVANCE

Withania somnifera (L.) Dunal (Solanaceae) is a traditional herb, used in African indigenous systems of medicine for the treatment of various diseases (including HIV/AIDS and tuberculosis). The relevance of clinically significant interactions of Withania with ARVs and anti-TB drugs needs to be investigated.

AIM OF THE STUDY

This study evaluated the effects of its roots on cytochromes P450 (CYPs) 2B6, 3A4, and rifampicin metabolism pathway, using methanol, ethanol, aqueous, and ethyl acetate solvent extractions.

MATERIALS AND METHODS

The extracts were tested on human liver microsomes (HLM) for CYP inhibition, mRNA expression in HepG2 cells for CYP induction. Biochemical qualitative tests and LC-MS/MS methodology were used to determine active phytoconstituents.

RESULTS

The methanolic and ethyl acetate extracts inhibited CYP2B6 with IC₅₀s 79.16 and 57.96 μg/ml respectively, while none of the extracts had any effect on rifampicin metabolism or showed time-dependant inhibition (TDI). All extracts were moderate inducers of CYP3A4; the aqueous extract exhibited 38%-fold shift induction of CYP3A4 compared to the control. The methanolic extract had the lowest CTC₅₀ (50% of cytotoxicity inhibition) (67.13 ± 0.83 μg/ml). LC-MS/MS-PDA full scans were consistent with the presence of flavone salvigenin (m/z 327), alkaloid isopelletierine (m/z 133), steroidal lactone 2,3-dihydrowithaferin-A (m/z 472), and other withanolides including withaperuvin I (m/z 533), withaferin derivative (m/z 567), some of these compounds likely being responsible for the observed CYP2B6 inhibition and CYP3A4 induction. The putative gastrointestinal tract (GIT) concentration for the active extracts was 1800 μg/ml and the hepatic circulation concentrations were estimated at about 220 μg/ml and 13.5 μg/ml for the methanolic and ethyl acetate extracts, respectively. The extrapolated in vivo percentage of inhibition was at 85% for the methanolic extract against CYP2B6.

CONCLUSIONS

The findings reported in this study suggest that W. somnifera extracts have the potential of causing clinically significant herb-drug interactions (HDI) as moderate inducer of CYP3A4 and inhibitor of CYP2B6 metabolism pathway (methanol and ethyl acetate extracts).

[Investigations into the distribution of neohistamine methylsulfate in the organism of the warm blooded animals following its intragastric administration]

The objective - of the present study was to elucidate the specific features of the distribution of neohistamine methylsulfate (proserin) in the organism of the omnivorous warm blooded animals following its intragastric administration. The analytical methods included TLC, HPLC, and UV-spectrophotometry. Neohistamine methylsulfate was administered intrgastrically to the male Wistar rats at a dose equivalent to the triple LD₅₀ dose. The substance of interest was extracted by acetone from the biological matrices of the dead animals and purified by sequential treatment with the relevant solvents and chromatography in a thin layer of the reverse-phase sorbent (C₁₄-C₁₅ bonded phase model) with the elution in the buffer solution (pH 1.98) - acetone (8:2) system. The compound of interest was identified based on the Rf values (obtained by TLC), retention time (in HPLC), and the spectral characteristics. The quantitative determination of the analyte in the biomatrices was performed with the use of UV spectrophotometry. The analytical methods were validated based on the criteria for linearity, selectivity, correctness, and precision as well as detection threshold and results of quantitation. The largest amount of the study compound were determined in the heart (365.2±33.94 mcg/g), spleen (288.6±24.97 mcg/g), kidney (127.6±9.33 mcg/g), and the gastric walls (124.6±12.17 mcg/g) of the experimental animals.